Clinical trials: Ovarian Tumor
HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood.
- Conditions
- HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer
- Trial name
- NCT00436254
- Testing
- pNGVL3-hICD vaccine, sargramostim, flow cytometry
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Washington
Polycystic Ovarian Syndrome (PCOS), Infertility
Theta Healing-Based Intervention in Women With Polycystic Ovary Syndrome
This randomized controlled study aims to evaluate the effect of a Theta Healing-based intervention on fertility concerns, self-compassion, and body image in women diagnosed with Polycystic Ovary Syndrome (PCOS).
- Conditions
- Polycystic Ovarian Syndrome (PCOS), Infertility, Psychological Stress
- Trial name
- NCT07630441
- Testing
- Theta Healing-Based Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 142 people
- Sponsor
- Ankara Medipol University
Polycystic Ovary Syndrome
Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
Polycystic ovary syndrome is one of the most common endocrine disorders, affecting about 6-10% of women in their reproductive age.
- Trial name
- NCT03630341
- Testing
- Clomiphene Citrate 50mg, L-carnitine
- Volunteers
- 150 people
- Sponsor
- Assiut University
Polycystic Ovary
The Supporting Understanding of PCOS Education and Research (SUPER) Study
This research will test whether a Dietary Approaches to Stop Hypertension (DASH) or a very low-carbohydrate diet better improves outcomes like blood glucose control and body weight for adults with polycystic ovary syndrome.
- Trial name
- SUPER (NCT05452642)
- Testing
- DASH diet, Very low-carbohydrate diet
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- University of Michigan
Ovarian Cancer
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
The purpose of the study is to evaluate the efficacy and toxicity of apatinib in patients with platinum resistant or refractory ovarian cancer when combined with etoposide.
- Trial name
- NCT02867956
- Testing
- Apatinib, Etoposide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer
The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.
- Trial name
- NCT00929162
- Testing
- ZD4054 Zibotentan, Paclitaxel, Carboplatin
- Where
- 20 sites in Germany, Italy
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Recurrent Ovarian Cancer
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
The purpose of this study is to evaluate the effectiveness and security of lobaplatin combined with docetaxel in treatment of the sensitive recurrent ovarian cancer.
- Trial name
- NCT01851746
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wuhan University
Ovarian Neoplasm
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
The purpose of the study is to see if the drug KU 0059436 is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and for whom no curative therapeutic option exists.
- Trial name
- ICEBERG 2 (NCT00494442)
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor)
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Cervical Carcinoma, Fallopian Tube Carcinoma
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for…
- Conditions
- Cervical Carcinoma, Fallopian Tube Carcinoma, Malignant Solid Neoplasm, Malignant Uterine Neoplasm
- Trial name
- NCT06492070
- Testing
- Best Practice, Cilostazol, Cryocompression Therapy
- Where
- 3 sites in United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Head and Neck Cancer, Melanoma
Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study
This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors.
- Conditions
- Head and Neck Cancer, Melanoma, Breast Cancer, Bladder Cancer
- Trial name
- YSCH-01 (NCT05180851)
- Testing
- Recombinant L-IFN adenovirus injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Fengxian District Central Hospital
Ovarian Neoplasms
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
The primary purpose is to assess the safety and tolerability of tilvestamab following IV administration of multiple doses to participants with HGSOC who have been treated with at least 1 complete course of platinum-based…
- Trial name
- NCT04893551
- Testing
- Tilvestamab
- Where
- 9 sites in Norway, Singapore and 2 more
- Volunteers
- 16 people
- Sponsor
- BerGenBio ASA
Ovarian Carcinoma
A Phase I Study of Intraperitoneal Hyperthermic Docetaxel
The primary objective is to assess the maximum tolerated dose of docetaxel administered intraperitoneally with heat at the time of second-look surgery in patients with stage II/III ovarian carcinoma.
- Trial name
- IP (NCT00474669)
- Testing
- docetaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Louisville
Adnexal Mass, Borderline Ovarian Epithelial Tumor
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer.
- Conditions
- Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor
- Trial name
- NCT02520115
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Valproic Acid
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Melanoma, Ovarian Cancer
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
This is a Phase I, multi-center, multiple ascending dose study to evaluate the clinical safety and immune response of IDC-G305 when injected intramuscularly in patients with unresectable or metastatic cancer.
- Conditions
- Melanoma, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer
- Trial name
- NCT02015416
- Testing
- IDC-G305
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with…
- Trial name
- NCT04457089
- Testing
- Simvastatin 40mg
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Marc Goodman
Ovarian Cancer, mRNA Vaccine
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
This is a Phase I, single-arm, open-label, prospective, non-randomized, single-center dose-escalation study. The study will evaluate the safety, tolerability, and preliminary activity of the NeoOVSV mRNA-lipid nanoparticle…
- Trial name
- NeoOVSV (NCT07724106)
- Testing
- Low Dose, middle dose, high dose
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Healthy
Measurement of the Folate Receptor in Blood
The folate receptor (FR) is a cell marker that is over expressed on the cell surface of certain cancers, this occurs most frequently in ovarian cancers.
- Trial name
- NCT00838747
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
There is a high prevalence of sexual and body image problems among women treated for gynecologic cancer, which can lead to considerable distress.
- Conditions
- Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms
- Trial name
- NCT01654458
- Testing
- GyneGals Support Group
- Where
- 7 sites in United States, Canada
- Volunteers
- 398 people
- Sponsor
- Women's College Hospital
Ovarian Cancer, Endometrial Cancer
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Rationale: The administration of prophylactic G-CSF may reduce the toxicity of a weekly paclitaxel/carboplatin regimen in gynaecological cancers.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Uterine Cervical Cancer
- Trial name
- NCT01523678
- Testing
- Filgrastim, Paclitaxel, Carboplatin
- Where
- 17 sites in Belgium
- Volunteers
- 108 people
- Sponsor
- Belgian Gynaecological Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.